Clinical Trial Update: Nivolumab for the Reversal of Squamous Dysplasia in High Risk Current and Former Smokers [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating nivolumab for reversal of squamous dysplasia in high-risk current and former smokers; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bronchial Dysplasia
• Head and Neck Squamous Cell Carcinoma
• Non-small Cell Lung Cancer

Drugs mentioned

• OPDIVO (nivolumab)

Snippet

Sponsor: University of Colorado, Denver | Conditions: Bronchial Dysplasia, Tobacco Smoking | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-12-12